Ã-mer KaradaÄž

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4044332/publications.pdf

Version: 2024-02-01

184 papers 4,131 citations

147801 31 h-index 58 g-index

189 all docs

189 docs citations

189 times ranked 5488 citing authors

#	Article	IF	Citations
1	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	27.0	687
2	Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine, 2008, 75, 291-294.	1.6	309
3	ldentification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	6.2	143
4	Severity of Carpal tunnel syndrome assessed with high frequency ultrasonography. Rheumatology International, 2010, 30, 761-765.	3.0	120
5	Behçet Disease With Vascular Involvement. Medicine (United States), 2015, 94, e494.	1.0	114
6	Are Familial Mediterranean Fever (FMF) Patients at Increased Risk for Atherosclerosis? Impaired Endothelial Function and Increased Intima Media Thickness Are Found in FMF. Journal of the American College of Cardiology, 2006, 48, 2351-2353.	2.8	108
7	Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatology International, 2012, 32, 323-330.	3.0	107
8	An International Multispecialty Validation Study of the IgG4â€Related Disease Responder Index. Arthritis Care and Research, 2018, 70, 1671-1678.	3.4	103
9	Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology, 2010, 49, 1889-1893.	1.9	97
10	Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-Â antagonist therapy: an ultrasound study. Rheumatology, 2010, 49, 578-582.	1.9	85
11	Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Annals of the Rheumatic Diseases, 2016, 75, 1051-1056.	0.9	83
12	A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. Journal of Rheumatology, 2015, 42, 1532-1534.	2.0	80
13	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> /i>/ <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	5.6	79
14	Reliability of high-resolution ultrasonography in the assessment of Achilles tendon enthesopathy in seronegative spondyloarthropathies. Annals of the Rheumatic Diseases, 2009, 68, 1850-1855.	0.9	73
15	Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment. Journal of Clinical Rheumatology, 2011, 17, 358-362.	0.9	73
16	A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. Journal of Rheumatology, 2020, 47, 117-125.	2.0	65
17	Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. Journal of Autoimmunity, 2016, 69, 59-63.	6.5	62
18	Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Research and Therapy, 2012, 14, R27.	3.5	60

#	Article	IF	CITATIONS
19	Impaired quality of life, disability and mental health in Takayasu's arteritis. Rheumatology, 2013, 52, 1898-1904.	1.9	53
20	Detection of Subclinical Cardiac Involvement in Systemic Sclerosis by Echocardiographic Strain Imaging. Echocardiography, 2008, 25, 191-197.	0.9	52
21	Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. Rheumatology, 2020, 59, 1372-1380.	1.9	51
22	Nationwide Experience With Offâ€Label Use of Interleukinâ€1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care and Research, 2018, 70, 1090-1094.	3.4	48
23	Management of Behcet's syndrome. Rheumatology, 2020, 59, iii108-iii117.	1.9	47
24	Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scandinavian Journal of Rheumatology, 2017, 46, 44-48.	1.1	46
25	Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases. Journal of Rheumatology, 2015, 42, 1661-1666.	2.0	43
26	The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatology International, 2013, 33, 893-897.	3.0	39
27	Sonographic assessment of carpal tunnel syndrome in rheumatoid arthritis: prevalence and correlation with disease activity. Rheumatology International, 2012, 32, 2313-2319.	3.0	37
28	Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scandinavian Journal of Infectious Diseases, 2007, 39, 475-478.	1.5	36
29	An unusual central nervous system involvement in rheumatoid arthritis: combination of pachymeningitis and cerebral vasculitis. Rheumatology International, 2009, 29, 1349-1353.	3.0	35
30	Assessment of latent tuberculosis infection in Takayasu arteritis with tuberculin skin test and Quantiferon-TB Gold test. Rheumatology International, 2010, 30, 1483-1487.	3.0	35
31	Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clinical Rheumatology, 2007, 26, 695-699.	2.2	33
32	Rituximab Experience in Patients With Long-standing Systemic Sclerosis–Associated Interstitial Lung Disease. Journal of Clinical Rheumatology, 2017, 23, 411-415.	0.9	33
33	Comparing polyarteritis nodosa in children and adults: a single center study. International Journal of Rheumatic Diseases, 2017, 20, 1016-1022.	1.9	30
34	Effect of anti-TNF treatment on sleep problems in ankylosing spondylitis. Rheumatology International, 2012, 32, 1909-1913.	3.0	29
35	Comparing immunoglobulin A vasculitis (Henoch–Schönlein purpura) in children and adults: a single-centre study from Turkey. Scandinavian Journal of Rheumatology, 2018, 47, 481-486.	1.1	29
36	Biochemical markers of bone turnover in diagnosis of myeloma bone disease. American Journal of Hematology, 2007, 82, 185-191.	4.1	28

#	Article	IF	Citations
37	B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?. Clinical Rheumatology, 2007, 26, 1701-1704.	2.2	27
38	QT dispersion increases in patients with systemic lupus erythematosus. Clinical Rheumatology, 2007, 26, 376-379.	2.2	26
39	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
40	Risk factors for malignancy in systemic sclerosis patients. Clinical Rheumatology, 2016, 35, 1529-1533.	2.2	24
41	Do ANCAâ€associated vasculitides and IgG4â€related disease really overlap or not?. International Journal of Rheumatic Diseases, 2019, 22, 1926-1932.	1.9	24
42	Vaccination recommendations for adult patients with rheumatic diseases. European Journal of Rheumatology, 2016, 3, 29-35.	0.6	24
43	Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity. Medicine (United States), 2018, 97, e9930.	1.0	21
44	Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. Journal of Neuroradiology, 2019, 46, 193-198.	1.1	21
45	Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?. Clinical Rheumatology, 2007, 26, 2059-2062.	2.2	20
46	Screening for latent tuberculosis infection in psoriasis and psoriatic arthritis patients in a tuberculosisâ€endemic country: a comparison of the Quanti <scp>FERON</scp> [®] â€ <scp>TB</scp> Gold Inâ€Tube test and tuberculin skin test. International Journal of Dermatology, 2014, 53, 1286-1292.	1.0	20
47	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. Pancreatology, 2021, 21, 1395-1401.	1.1	20
48	Assessment of Patients with Takayasu Arteritis in Routine Practice with Indian Takayasu Clinical Activity Score. Journal of Rheumatology, 2015, 42, 1443-1447.	2.0	19
49	Left and Right Ventricular Function Is Impaired in Behçet's Disease. Echocardiography, 2006, 23, 723-728.	0.9	18
50	Relationship of ultrasonographic findings with synovial angiogenesis modulators in different forms of knee arthritides. Rheumatology International, 2013, 33, 879-885.	3.0	18
51	Inflammatory bowel diseases and Takayasu's arteritis: coincidence or association?. International Journal of Rheumatic Diseases, 2016, 19, 814-818.	1.9	18
52	A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. Rheumatology International, 2018, 38, 1833-1840.	3.0	18
53	Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study. Clinical Rheumatology, 2019, 38, 1699-1706.	2.2	18
54	Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 675-676.	0.9	17

#	Article	IF	CITATIONS
55	Increased serum vitamin B12 levels are associated with adult-onset Still's disease with reactive macrophage activation syndrome. Joint Bone Spine, 2010, 77, 131-134.	1.6	16
56	Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study. European Journal of Rheumatology, 2014, 49, 51-54.	0.6	16
57	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39, 32-38.	0.8	16
58	Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience. Multiple Sclerosis and Related Disorders, 2020, 38, 101512.	2.0	15
59	Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. Leukemia and Lymphoma, 2005, 46, 1825-1828.	1.3	14
60	Research for bleeding tendency in patients presenting with significant epistaxis. Blood Coagulation and Fibrinolysis, 2007, 18, 41-43.	1.0	14
61	Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology, 2016, 3, 25-28.	0.6	14
62	Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 90-94.	0.8	13
63	Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 135-142.	0.8	13
64	Anterior Abdominal Wall Synovial Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 323-324.	1.3	12
65	Hemorrhage into a Thyroid Nodule as a Cause of Thyrotoxicosis. Endocrine Practice, 2006, 12, 299-301.	2.1	12
66	Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2011, 14, 379-383.	1.9	12
67	Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. Rheumatology International, 2009, 29, 777-780.	3.0	11
68	Increased psoriasis frequency in patients with familial Mediterranean fever. Upsala Journal of Medical Sciences, 2018, 123, 57-61.	0.9	11
69	Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes. European Journal of Rheumatology, 2018, 5, 32-36.	0.6	11
70	Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turkish Journal of Medical Sciences, 2021, 51, 297-308.	0.9	11
71	Appropriate utilization of hospital beds in internal medicine: evaluation in a tertiary care hospital. Journal of Evaluation in Clinical Practice, 2007, 13, 408-411.	1.8	10
72	Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases. Rheumatology International, 2015, 35, 1083-1092.	3.0	10

#	Article	IF	CITATIONS
73	lgG4-related disease in pediatric patients: a single-center experience. Rheumatology International, 2022, 42, 1177-1185.	3.0	10
74	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. American Journal of Ophthalmology, 2021, 228, 58-64.	3.3	10
75	Isolated granulocytic sarcoma of the head and neck preceding acute myeloid leukemia. American Journal of Hematology, 2004, 76, 95-96.	4.1	9
76	Anaplastic large cell lymphoma presenting with symmetric polyarthritis in pregnancy. Rheumatology International, 2008, 28, 909-911.	3.0	9
77	The clinical features and outcomes of Turkish patients with IgG4-related disease:a single-center experience. Turkish Journal of Medical Sciences, 2017, 47, 1307-1314.	0.9	9
78	Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis. Biomolecules, 2018, 8, 136.	4.0	9
79	Geoepidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients' data. Turkish Journal of Medical Sciences, 2020, 44, 281-290.	0.9	9
80	Polyarteritis nodosa: lessons from 25 years of experience. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 52-56.	0.8	9
81	Reliability assessment of the definition of ultrasound enthesitis in SpA: results of a large, multicentre, international, web-based study. Rheumatology, 2022, 61, 4863-4874.	1.9	9
82	Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole: a case report. European Journal of Clinical Pharmacology, 2004, 60, 455-456.	1.9	8
83	Increased incidence of spondyloarthropathies in patients with Takayasu arteritis: a systematic clinical survey. Joint Bone Spine, 2019, 86, 497-501.	1.6	8
84	Systemic involvements and preferred treatments in a large cohort of Behçet's disease. Rheumatology International, 2013, 33, 3025-3030.	3.0	7
85	Aspirin resistance in systemic lupus erythematosus. A pilot study. Lupus, 2013, 22, 835-838.	1.6	7
86	Orbital Involvement and Ocular Surface Changes in IgG4-Related Systemic Disease. Cornea, 2016, 35, 1449-1453.	1.7	7
87	Methodology of a new inflammatory arthritis registry: TReasure. Turkish Journal of Medical Sciences, 2018, 48, 856-861.	0.9	7
88	Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature. Acta Clinica Belgica, 2019, 74, 364-369.	1.2	7
89	Successful Treatment of Amyloid A–Type Amyloidosis Due to Behçet Disease With Tocilizumab. Journal of Clinical Rheumatology, 2019, 25, e43-e45.	0.9	7
90	Predictive factors for workâ€day loss in Behçet's syndrome: A multiâ€center study. International Journal of Rheumatic Diseases, 2020, 23, 240-246.	1.9	7

#	Article	lF	CITATIONS
91	Cancer incidence in Behçet's disease. Irish Journal of Medical Science, 2020, 189, 1209-1214.	1.5	7
92	Predictors for the risk and severity of post-thrombotic syndrome in vascular Behçet's disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 1451-1459.	1.6	7
93	Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. Autoimmunity Reviews, 2021, 20, 102783.	5.8	7
94	Coronary (peri)â€arteritis in patients with IgG4â€related disease: A case series from the Central Anatolia Region of Turkey. International Journal of Rheumatic Diseases, 2021, 24, 1004-1013.	1.9	7
95	Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Turk Kardiyoloji Dernegi Arsivi, 2018, 46, 358-365.	0.5	7
96	Erythroderma related with the first dose of Pfizerâ∈BioNTech BNT16B2b2 COVIDâ€19 mRNA vaccine in a patient with psoriasis. Dermatologic Therapy, 2022, 35, e15363.	1.7	7
97	Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 77-82.	0.8	7
98	Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry. Clinical Rheumatology, 2019, 38, 1187-1192.	2.2	6
99	Interferon alpha might be an alternative therapeutic choice for refractory Neuro-Behçet's disease. Multiple Sclerosis and Related Disorders, 2019, 29, 153.	2.0	6
100	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.9	6
101	Rare occupational cause of nasal septum perforation: Nickel exposure. International Journal of Occupational Medicine and Environmental Health, 2017, 30, 963-967.	1.3	6
102	Serum lipid changes and insulin resistance in familial Mediterranean fever. European Journal of Rheumatology, 2014, 1, 140-143.	0.6	6
103	Effect of capillaroscopic patterns on the pulse oximetry measurements in systemic sclerosis patients. Microvascular Research, 2015, 98, 183-186.	2.5	5
104	Blood group  A' may have a possible modifier effect on familial Mediterranean fever and blood group  0' may be associated with colchicine resistance. Biomarkers in Medicine, 2018, 12, 565-572.	1.4	5
105	Imaging modalities used in diagnosis and follow-up of patients with Takayasu's arteritis. Turkish Journal of Medical Sciences, 2021, 51, 224-230.	0.9	5
106	Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). European Journal of Rheumatology, 2015, 2, 149-154.	0.6	5
107	5-Fluorouracil-Induced Coronary Spasm: May Inhibition of Hyperpolarization Factors Produced by CYP2C Enzymes Be the Cause?. Oncology, 2004, 66, 510-511.	1.9	4
108	Macrophage inflammatory protein- $1\hat{l}_{\pm}$: A link between innate immunity and familial mediterranean fever?. Cytokine, 2007, 37, 92-95.	3.2	4

#	Article	IF	Citations
109	Serum adenosine deaminase activities during acute attacks and attack-free periods of familial Mediterranean fever. European Journal of Internal Medicine, 2009, 20, 44-47.	2.2	4
110	Aspergillus Pneumonia in a Patient With Adult-Onset Still Disease Successfully Treated With Anakinra. Journal of Clinical Rheumatology, 2018, 24, 156-158.	0.9	4
111	Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?. Annals of the Rheumatic Diseases, 2023, 82, e85-e85.	0.9	4
112	Anti-interleukin-6 (tocilizumab) therapy in Takayasu's arteritis: real-life experience. Turkish Journal of Medical Sciences, 2020, 50, 31-36.	0.9	4
113	Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid. Turkish Journal of Medical Sciences, 2020, 50, 219-224.	0.9	4
114	QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. Clinical Rheumatology, 2021, 40, 2027-2035.	2.2	4
115	Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clinical Rheumatology, 2022, 41, 85-94.	2.2	4
116	Moderation analysis exploring associations between age and mucocutaneous activity in Behçet's syndrome: A multicenter study from Turkey. Journal of Dermatology, 2020, 47, 1403-1410.	1.2	4
117	The presence of <i>MEFV </i> i>gene mutations in patients with primary osteoarthritis who require surgery. Korean Journal of Internal Medicine, 2013, 28, 594.	1.7	4
118	Use of musculoskeletal ultrasound in rheumatoid arthritis in Turkey among rheumatologists: A national targeted ultrasound initiative survey. European Journal of Rheumatology, 2015, 2, 43-44.	0.6	4
119	Tuberculous bursitis of the greater trochanter mimicking ankylosing spondylitis. European Journal of Rheumatology, 2015, 2, 31-32.	0.6	4
120	A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome. Seminars in Arthritis and Rheumatism, 2022, 52, 151924.	3.4	4
121	PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey. Clinical and Experimental Rheumatology, 2012, 30, S11-4.	0.8	4
122	Comprehensive assessment and outcomes of patients with chronic periaortitis. Clinical and Experimental Rheumatology, 0 , , .	0.8	4
123	Autoimmune Polyendocrine Syndrome With Atrial Septal Defect. American Journal of the Medical Sciences, 2008, 335, 157-159.	1.1	3
124	Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 103-108.	1.7	3
125	Nasopharyngeal sarcoidosis: a rare involvement. Rheumatology International, 2012, 32, 1407-1409.	3.0	3
126	Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis?. Clinical Rheumatology, 2012, 31, 225-229.	2.2	3

#	Article	IF	Citations
127	P1_145 Two-year Results of a Prospective Vasculitis Cohort from Eastern Mediterranean: Demographic Characteristics and Distribution of the Vasculitides Frequencies. Rheumatology, 2017, 56, iii88-iii95.	1.9	3
128	Capillaroscopic findings in Turkish Takayasu arteritis patients. Turkish Journal of Medical Sciences, 2019, 49, 1303-1307.	0.9	3
129	The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?. Internal and Emergency Medicine, 2022, 17, 743-751.	2.0	3
130	Seroprevalence of Hepatitis B and C among Patients Admitted to a Tertiary Hospital. Viral Hepatitis Journal, 2014, 20, 120-124.	0.1	3
131	Oral ulcer activity assessment with the composite index according to different treatment modalities in Behçet's syndrome: a multicentre study. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 98-104.	0.8	3
132	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 32-38.	0.8	3
133	Two cases of glutaric aciduria type II: how to differentiate from inflammatory myopathies?. Acta Clinica Belgica, 2019, 74, 451-455.	1.2	2
134	Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-1± biologics: real-life results from a single-centre cross-sectional study. Rheumatology International, 2020, 40, 1501-1507.	3.0	2
135	Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease?. Internal and Emergency Medicine, 2022, 17, 1599-1608.	2.0	2
136	Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. Rheumatology, 2022, 62, 341-346.	1.9	2
137	Comment on: Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology, 2012, 51, 955-955.	1.9	1
138	IgG4-related sclerosing disease with mesenteric and retroperitoneal involvement. Egyptian Journal of Radiology and Nuclear Medicine, 2017, 48, 767-769.	0.6	1
139	AB0574â€A MONOGENIC DISEASE WITH WIDE RANGE OF SYMPTOMS: DEFICIENCY OF ADENOSINE DEAMINAS 2., 2019,,.	Έ	1
140	SAT0372â€CHANGE OF SUBCLINICAL ATHEROSCLEROSIS AFTER FIVE YEARS ANTI-TNF TREATMENTS IN PSORIAT ARTHRITIS., 2019,,.	ПС	1
141	Some concerns from Turkey. Annals of the Rheumatic Diseases, 2020, 79, e15-e15.	0.9	1
142	Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.9	1
143	Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. Acta Medica, 0, 52, 4-6.	0.2	1
144	lliac artery aneurysm in Behçet's syndrome: collaborative management is essential. Rheumatology, 2021, 60, iii32-iii34.	1.9	1

#	Article	IF	CITATIONS
145	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
146	Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis. European Journal of Rheumatology, 2018, 5, 75-78.	0.6	1
147	Multiple liver masses mimicking metastatic liver disease in an elderly patient. Turkish Journal of Gastroenterology, 2018, 29, 117-120.	1.1	1
148	How Did The Updated Haemodynamic Definitions Affect The Frequency Of Pulmonary Hypertension In Patients With Systemic Sclerosis?. Anatolian Journal of Cardiology, 2020, 25, 30-35.	0.9	1
149	Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results. Clinical Rheumatology, 2022, , 1.	2.2	1
150	Comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Sebastiani et al Clinical and Experimental Rheumatology, 2021, 39, 196-196.	0.8	1
151	Comprehensive assessment and outcomes of patients with chronic periaortitis Clinical and Experimental Rheumatology, 2022, , .	0.8	1
152	Volume plaquettaire moyenÂ: un marqueur de l'inflammation dans la spondylarthrite ankylosante et la polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 424-427.	0.0	0
153	Nurse-Guided Completion of the BASDAI Questionnaire in Ankylosing Spondylitis Patients with Low Literacy. Journal for Nurse Practitioners, 2010, 6, 201-205.	0.8	O
154	Comment on: Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-Â antagonist therapy: an ultrasound study: reply. Rheumatology, 2010, 49, 1419-1420.	1.9	0
155	Comment on: The value of colour Doppler sonography of the knee joint: a useful tool to discriminate inflammatory from non-inflammatory disease?. Rheumatology, 2013, 52, 2099-2100.	1.9	O
156	An Unusual Clinical Presentation of Amyloidosis: Auricular Concha Involvement. Journal of Rheumatology, 2014, 41, 140-140.	2.0	0
157	The Rheumatologist's Perspective In Diagnostic Course and Management of Familial Mediterranean Fever. Value in Health, 2015, 18, A676.	0.3	O
158	A rare cause of proximal muscle weakness: immune necrotising myopathy. Scottish Medical Journal, 2018, 63, 82-86.	1.3	0
159	THU0565â€COMPARISON OF SURVIVAL RATES AMONG SUBGROUPS OF PATIENTS EVALUATED FOR FEVER OF UNKNOWN ORIGIN., 2019,,.		O
160	SAT0214â€CLINICAL FEATURES OF ANEURYSMAL BEHÇET DISEASE. , 2019, , .		0
161	FRIO395â€SWITCHING RATE OF ANTI-TNF AGENTS IN SPONDYLOARTHRITIS PATIENTS: TREASURE – REAL LIFE DATA. , 2019, , .		O
162	THU0410â€UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS., 2019, , .		0

#	Article	IF	CITATIONS
163	FRI0098â€SWITCHING RATE OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS: TREASURE – RELIFE DATA. , 2019, , .	EAL	0
164	THU0287â€ANEURYSM IN BEHÇET'S DISEASE: MANAGEMENT, PROGNOSIS AND MORTALITY. , 2019, , .		0
165	THU0387â€ENTEROPATHIC ARTHRITIS PATIENTS UNDER BDMARD TREATMENTS HAD FREQUENTLY RADIOGRAPHIC SACROILIITIS: HUR-BIO REAL LIFE RESULTS. , 2019, , .		O
166	AB0723â€SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA. , 2019, , .		0
167	SAT0233â€VALIDATION OF A NOVEL DISEASE CLASSIFICATION IN HACETTEPE TAKAYASU ARTERITIS COHORT. , 2019, , .		0
168	FRIO589â€IS THERE AN OVERLAP OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIDES WITH IGG4-RELATED DISEASE OR NOT?. , 2019, , .		0
169	SAT0221â€OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY POLYARTERITIS NODOSA. , 2019, , .		0
170	Adalimumab as Treatment for Venous Thrombosis in Beh \tilde{A} et's Syndrome: Comment on the Article by Emmi et al. Arthritis and Rheumatology, 2019, 71, 657-657.	5.6	0
171	Frequency of Behçet's disease among a group of visually impaired adults. Irish Journal of Medical Science, 2019, 188, 333-336.	1.5	0
172	Incidence croissante des spondyloarthropathies chez les patients présentant une artérite de TakayasuÂ: sondage clinique systématique. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 116-121.	0.0	0
173	Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions. Internal and Emergency Medicine, 2021, 16, 33-35.	2.0	0
174	Successful treatment of penile Mondor's disease with infliximab in a patient with Behçet's disease. Rheumatology, 2021, 60, e400-e401.	1.9	0
175	Successful treatment of primary Sjogren's syndrome complicated with primary biliary cirrhosis and lung involvement. Turkish Journal of Gastroenterology, 2010, 21, 60-62.	1.1	O
176	Evaluation of relationship between peripheral neuropathy and digital ulcer formation in patients with systemic sclerosis. Ulusal Romatoloji Dergisi, 2020, 12, 76-82.	0.0	0
177	Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry. Clinical and Experimental Rheumatology, 2020, 38, 609-614.	0.8	0
178	Comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 128, 8.	0.8	0
179	Comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Sebastiani et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 196.	0.8	O
180	Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al. Clinical and Experimental Rheumatology, 2021, , .	0.8	0

#	Article	IF	CITATIONS
181	Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al Clinical and Experimental Rheumatology, 0, , .	0.8	O
182	The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results. Ulusal Romatoloji Dergisi, 2021, 13, 107-115.	0.0	0
183	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	3.0	O
184	The performance of IgG4-related disease responder index in children. Clinical and Experimental Rheumatology, 0 , 0 .	0.8	0